Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2026)

Crinetics Pharmaceuticals' Non-Current Assets history runs 10 years deep, the most recent figure standing at $78.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 12.29% year-over-year to $78.9 million; the TTM figure through Mar 2026 stood at $303.9 million (up 21.55% YoY), while the FY2025 annual figure was $77.9 million, up 31.6% from the prior year.
• Non-Current Assets was $78.9 million for Q1 2026 at Crinetics Pharmaceuticals, up from $77.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $78.9 million in Q1 2026 to a low of $5.0 million in Q1 2022.
• Historically, Non-Current Assets has averaged $46.1 million across 5 years, with a median of $60.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets slipped 12.34% in 2022, then soared 903.16% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $7.0 million in 2022, then surged by 775.29% to $61.2 million in 2023, then slipped by 3.26% to $59.2 million in 2024, then soared by 31.6% to $77.9 million in 2025, then rose by 1.28% to $78.9 million in 2026.
• The last three Non-Current Assets figures came in at $78.9 million (Q1 2026), $77.9 million (Q4 2025), and $74.8 million (Q3 2025), per Business Quant data.